4.5 Article

Recombinant human lactoferrin carrying humanized glycosylation exhibits antileukemia selective cytotoxicity, microfilament disruption, cell cycle arrest, and apoptosis activities

Journal

INVESTIGATIONAL NEW DRUGS
Volume 39, Issue 2, Pages 400-415

Publisher

SPRINGER
DOI: 10.1007/s10637-020-01020-2

Keywords

Apoptosis; Cancer; Cell cycle; Cytoskeleton; DNA fragmentation; Drug discovery; Humanized proteins

Funding

  1. Consejo Nacional de Ciencia y Tecnologia (CONACyT), Mexico
  2. Facultad de Ciencias Quimicas, at the Universidad Autonoma de Chihuahua, Mexico
  3. Lizanell and Colbert Coldwell Foundation
  4. National Institute of General Medical Sciences-Support of Competitive Research (SCORE) [1SC3GM103713]
  5. National Institute on Minority Health and Health Disparities, a component of the National Institutes of Health [5G12MD007592, 5U54MD007592]

Ask authors/readers for more resources

The research shows that rhLf-h-glycan has potential toxicity against cancer cells, exhibiting selective cytotoxicity towards cancer cells while sparing normal cells. It also demonstrates significant anti-proliferative activity and induces apoptosis in cancer cells under experimental conditions.
Lactoferrin has gained extensive attention due to its ample biological properties. In this study, recombinant human lactoferrin carrying humanized glycosylation (rhLf-h-glycan) expressed in the yeastPichia pastorisSuperMan5, which is genetically glycoengineered to efficiently produce functional humanized glycoproteins inclosing (Man)(5)(GlcNAc)(2)Asn-linked glycans, was analyzed, inspecting its potential toxicity against cancer cells. The live-cell differential nuclear staining assay was used to quantify the rhLf-h-glycan cytotoxicity, which was examined in four human cell lines: acute lymphoblastic leukemia (ALL) CCRF-CEM, T-cell lymphoblastic lymphoma SUP-T1, cervical adenocarcinoma HeLa, and as control, non-cancerous Hs27 cells. The defined CC(50)values of rhLf-h-glycan in CCRF-CEM, SUP-T1, HeLa, and Hs27 cells were 144.45 +/- 4.44, 548.47 +/- 64.41, 350 +/- 14.82, and 3359.07 +/- 164 mu g/mL, respectively. The rhLf-h-glycan exhibited a favorable selective cytotoxicity index (SCI), preferentially killing cancer cells: 23.25 for CCRF-CEM, 9.59 for HeLa, and 6.12 for SUP-T1, as compared with Hs27 cells. Also, rhLf-h-glycan showed significant antiproliferative activity (P < 0.0001) at 24, 48, and 72 h of incubation on CCRF-CEM cells. Additionally, it was observedviafluorescent staining and confocal microscopy that rhLf-h-glycan elicited apoptosis-associated morphological changes, such as blebbing, nuclear fragmentation, chromatin condensation, and apoptotic bodies in ALL cells. Furthermore, rhLf-h-glycan-treated HeLa cells revealed shrinkage of the microfilament structures, generating a speckled/punctuated pattern and also caused PARP-1 cleavage, a hallmark of apoptosis. Moreover, in ALL cells, rhLf-h-glycan altered cell cycle progression inducing the G2/M phase arrest, and caused apoptotic DNA fragmentation. Overall, our findings revealed that rhLf-h-glycan has potential as an anticancer agent and therefore deserves furtherin vivoevaluation.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available